Following MicrosensDx’s announcement of the publication of clinical data on its rapid testing kit for COVID-19 with the potential to transform detection methods, CEO Dr Christopher Stanley was interviewed by Anna MacDonald at Technology Networks to learn more about the RapiPREP® COVID-19 test, the results of the trial, and the difference point-of-care testing could make to the response to the pandemic.

Read the full interview here